Optum, Eden Prairie, MN 55344, USA.
Myriad Genetics Laboratories, Salt Lake City, UT 84108, USA.
J Comp Eff Res. 2021 Feb;10(3):207-217. doi: 10.2217/cer-2020-0192. Epub 2021 Jan 25.
Healthcare utilization and costs were compared following 25-gene panel (panel) or single syndrome (SS) testing for hereditary breast and ovarian cancer. Retrospective cohort study of patients unaffected by cancer with panel (n = 6359) or SS (n = 4681) testing for hereditary breast and ovarian cancer (01 January 2014 to 31 December 2016). Groups were determined by test type and result (positive, negative, variant of uncertain significance [VUS]). There were no differences in total unadjusted healthcare costs between the panel (US$14,425) and SS (US$14,384) groups (p = 0.942). Among VUS patients in the panel and SS groups, mean all-cause costs were US$14,404 versus US$20,607 (p = 0.361) and mean risk-reduction/early detection-specific costs were US$718 versus US$679 (p = 0.890), respectively. Adjusted medical costs were not significantly different between panel and SS cohorts. Healthcare utilization and costs were comparable between the SS and panel tests overall and for patients with VUS.
对遗传性乳腺癌和卵巢癌进行 25 基因panel 检测（panel）或单基因综合征（SS）检测后，比较了医疗保健的使用情况和费用。
对未患癌症的患者进行回顾性队列研究，这些患者进行了遗传性乳腺癌和卵巢癌的 panel（n=6359）或 SS（n=4681）检测（01 年 1 月 2014 日至 12 月 31 日 2016 年）。组别的确定依据是测试类型和结果（阳性、阴性、意义不明的变异体[VUS]）。panel（US$14425）和 SS（US$14384）组之间的未调整医疗保健总成本无差异（p=0.942）。在 panel 和 SS 组中 VUS 患者中，全因成本的平均值分别为 US$14404 与 US$20607（p=0.361），风险降低/早期检测特异性成本的平均值分别为 US$718 与 US$679（p=0.890）。调整后的医疗费用在 panel 和 SS 队列之间没有显著差异。总体而言，SS 和 panel 检测的医疗保健利用和费用在 VUS 患者中是可比的。
